Navigation Links
CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
Date:10/15/2009

ocrine pancreatic insufficiency in children with CF to help maintain adequate nutrition and normal growth," said Gavin Graff M.D.

While CREON® is already FDA-approved and indicated for the treatment of EPI due to CF and other conditions in patients ages zero and above, Solvay Pharmaceuticals is committed to the continued clinical study and development of CREON® as further confirmation of the safety and efficacy of pancreatic enzyme replacement therapies (PERTs) as described in medical literature and through clinical experience.

The safety and efficacy of PERTs with different formulations of pancrelipase consisting of the same active ingredient as CREON® (lipases, proteases, and amylases) for treatment of children with exocrine pancreatic insufficiency due to cystic fibrosis have been described in the medical literature and through clinical experience. There is a history of using different formulations of CREON® to treat pediatric patients with EPI due to CF, which has demonstrated efficacy and safety in those patients through years of clinical experience.

In addition to the supplemental CREON® pediatric data, data which supported the recent FDA approval of CREON® are also being presented at NACFC in a poster authored by Dr. Bruce Trapnell, entitled "Pancrelipase delayed-release capsules (CREON®) in patients with pancreatic insufficiency due to cystic fibrosis: Age and severity analyses," during the general poster sessions.

Pediatric Study Details

The double-blind, randomized, multi-center, placebo-controlled, cross-over study examined the efficacy and safety of CREON® (pancrelipase) Delayed-Release 12,000 lipase unit capsules in 16 subjects ages 7-11 years with EPI due to CF. EPI was confirmed in all subjects by a CFA of <70% without pancreatic enzyme supplementation or pancreatic elastase <50 micrograms/gram stool within 12 months prior to start of stud
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
2. Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets
3. Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA
4. GSK Receives Approval for HYCAMTIN(R) (topotecan) Capsules for the Treatment of Relapsed Small Cell Lung Cancer
5. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
6. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
7. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
8. First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
9. New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
10. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
11. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, ... Dow Jones Industrial Average finished the day 0.42% lower at ... The losses were broad based as eight out of ten ... Care Sector Index ended the day at 711.88, down 0.02%, ... month. Investor-Edge has initiated coverage on the following equities: Covidien ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... July 12, 2011 Particle Sciences ... Systems, a leading provider of pre-clinical pharmacokinetic services, ... together to provide their clients with enhanced drug ... the dosage form development scheme.   ...
... Helping Virologists Keep,Up- to- Date ... Elsevier ( http://www.elsevier.com ) has,announced the publication of the first ... in its prestigious Current Opinion,series, publishing six issues a year. ... filtered approach to the ever-expanding wealth of research,published on viruses and ...
Cached Medicine Technology:Particle Sciences and Absorption Systems Form Relationship to Offer their Clients Enhanced Services 2Elsevier Launches Current Opinion in Virology 2
(Date:7/12/2014)... "The second toes cross over the big toes ... shoes," said an inventor from East Hartford, Conn. This gave ... happening. , He then created a prototype of the Comfort ... and big toes from overlapping. This avoids discomfort and pain, ... easy to use, it's ideal for people with foot problems, ...
(Date:7/12/2014)... my mom’s stroke, she loss the use of her right side. ... his left side. Eating became a difficult task for them so ... enjoy eating again,” said an inventor, from Fayetteville, N.C. As a ... (P C H PLATE). , The PATRICIA CAROL HALL PLATE (P ... individuals who suffer from stroke, experience tremors or loss of movement. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... Beverly Hills, CA (PRWEB) July 12, 2014 ... reason why are bodies can readily absorb the nutrients in ... into tiny particles that are small enough to be absorbed ... the DZ10 team, a lack of enzymes in regular food ... DZ10 is a product that was started by Michelle DelPresto, ...
(Date:7/12/2014)... Albany, NY (PRWEB) July 12, 2014 ... to 2020 - New and Late-Stage Four-Factor PCCs ... in-depth analysis of the critical care market in ... and Canada. The report provides an estimation of ... to 2020. It covers critical care indications that ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:New Super Digestive Enzyme, DZ10, Supercharges The Digestion Process 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... progression, mouse study suggests , , MONDAY, April 14 (HealthDay ... cholesterol and one is an anti-inflammatory -- may be ... presented at the American Association for Cancer Research annual ... and the statin Lipitor, when used together or alone, ...
... Kimmel Cancer Center at Thomas Jefferson University in ... blood pressure medications might help prevent the spread ... laboratory that one type of pressure-lowering drug called ... growth and causes cell death. , In earlier ...
... Real-Time In Vivo Data via Quantitative ... ... Inc., a leader,in fluorescence in vivo imaging, today announced the commercial ... is based on VisEn,s,proprietary Fluorescence Molecular Tomography (FMT(TM)) technology,platform, and combined ...
... 14 HealthFusion, a,national clearinghouse for ... center operation customer satisfaction excellence under ... Center Program(SM). This distinction,acknowledges a strong ... to provide "An Outstanding Customer Service ...
... As the first of the,nation,s 78 million baby boomers ... health care work force that is too small and ... new report from the Institute of,Medicine. The report calls ... providers -- not just specialists -- in the basics ...
... Denise Kehoe has joined,medication therapy management (MTM) company ... new role, she will manage and oversee the,expansion ... the country., Kehoe brings more than 15 ... PharmMD. She recently served as national strategic,executive of ...
Cached Medicine News:Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 2Health News:Celebrex Plus Lipitor Could Fight Prostate Cancer 3Health News:Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find 2Health News:VisEn Medical Launches FMT(TM) 2500 - Next-Generation Fluorescence Imaging System 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 2Health News:J.D. Power and Associates Reports: HealthFusion Recognized for Providing an Outstanding Customer Service Experience 3Health News:Health Care Work Force Too Small, Unprepared for Aging Baby Boomers; Higher Pay, More Training, and Changes in Care Delivery Needed to Avert Crisis 2Health News:PharmMD Announces Denise Kehoe as Vice President of Business Development 2
Attachments: Clip bar for tubes 10 to 19 mm in diameter Overall Dimension Height IC: 6 (15.2) Overall Dimension Length IC: 18.5 (46.9) Overall Dimension Width IC: 4 (10.2)...
... The model 55S Rocking Shaker ... gels and blotted membranes. The very ... adjustable degree of tilt provide a ... washes over gels and blotted membranes ...
Adjustable tilt angle 0 to 20 Adjustable speed of 3-25 RPM Load capacity: 2.7 kg (6 lbs.) Ambient temperature range 4C to 65C Low voltage power is supplied by wall mount transformer...
... bacterial growth system, combines orbital shaking, ... format for bacterial growth. It is ... HT-Prep™ Automatic DNA Extractor. The uniquely ... traditional floor shakers. Plate-holding cassettes allow ...
Medicine Products: